Catalyst Dossier · compiled by CeliA 🧫
MERCK (MRK)
Pharmaceutical Preparations · market cap $281.2B · as of 2026-07-13
Research and calibrated estimates, not financial advice — verify before acting.
Next catalyst
2026-10-30 (est.)
Phase 2
Pipeline
20
programs
Upcoming events
8
next 90d+
Dossier
Ready
cached
Merck & Co. (MRK) is a top-five global pharma by revenue, generating $65B in 2025 sales with a $305B market cap. The company carries a substantial net debt load of ~$43.8B against $5.3B cash, and its near-term catalyst calendar is anchored by a high-importance Phase 3 SC Tulisokibart readout (Aug 1) and a Phase 3 pembrolizumab data point (Oct 28). Recent Phase 3 results on July 6 were mixed — four positives and two negatives — underscoring the breadth and variability of its pipeline.
The catalyst path
- 2026-10-30 (est.)Phase 2 · GAd-209-FSP low doseimp 7/10
- 2026-10-31 (est.)Phase 2 · Lenvatinibimp 7/10
- 2026-12-01 (est.)Phase 2 · Axatilimabimp 7/10
- 2026-12-15 (est.)Phase 2 · TU2218 + KEYTRUDA® (Pembrolizumab)imp 7/10
- 2026-12-23 (est.)Phase 2 · Lenvatinibimp 7/10
- 2026-12-30 (est.)Phase 2 · Encorafenib Oral Capsule + Cetuximabimp 7/10
- 2027-01-04 (est.)Phase 3 · Trifluridine-Tipiracilimp 9/10
- 2027-01-15 (est.)Phase 2 · Olaparibimp 7/10
Pipeline
| Asset | Phase | Indication |
|---|---|---|
| Lonafarnib | Phase 2 | Breast Cancer |
| Arm A: Pemetrexed Cisplatin | Phase 2 | Non Small Cell Lung Cancer |
| EVX-01 | Phase 2 | Melanoma Stage IV |
| PembroRT | Phase 2 | Non-small Cell Lung Cancer, NSCLC |
| Brexucabtagene autoleucel ( other names: brexu-cel , Tecartus) | Phase 2 | Recurrent Mantle Cell Lymphoma |
| MK1903 | Phase 2 | Dyslipidemia |
| MK-2206 | Phase 2 | PANCREAS |
| Elbasvir | Phase 3 | Hepatitis C |
| Peginterferon alfa-2a (Peg-IFN) | Phase 2 | Hepatitis C, Chronic |
| denufosol tetrasodium Inhalation Solution | Phase 2 | Cystic Fibrosis |
| CXA-101 | Phase 2 | Complicated Urinary Tract Infection |
| V260 | Phase 3 | Rotavirus Gastroenteritis |
| Vericiguat tablet | Phase 3 | Heart Failure |
| MK0524A, niacin (+) laropiprant / Duration of Treatment : 4 Weeks | Phase 2 | Hypercholesterolemia |
| pegylated interferon | Phase 2 | Chronic Hepatitis C |
| Pegylated interferon alfa-2b (SCH 54031) | Phase 3 | Hepatitis C, Chronic |
| MK-8591A | Phase 3 | HIV-1 Infection |
| Multiple low dose cyclophosphamide | Phase 2 | Multiple Myeloma |
| Surotomycin | Phase 3 | Clostridium Difficile Infection |
| Prevenar 13™ | Phase 3 | Pneumococcal Infections |
Price & technical context
3-month
+29.0%
6-month
+28.6%
12-month
+81.0%
52-wk range
$77.60–$156.45
vs 50-day MA
+6.5%
vs 200-day MA
+21.9%
Realized vol
30.0%
Max drawdown
-38.1%
Daily closes through 2026-09-18. Realized vol annualized; max drawdown over ~2 years.
The full dossier is a Pro feature
Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.
Sources & data
- SEC filings — EDGAR filings for MRK (10-K, 10-Q, S-3, 13D/G, Form 4)
- Clinical trials — 20 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
- Market & financial data — Financial Modeling Prep / financialdata.net — prices, statements, key metrics, insider & institutional filings.
- Regulatory — openFDA, FDA advisory & PDUFA calendars.
Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.
Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, Financial Modeling Prep). Compiled by CeliA. Not financial advice.